{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:08:17Z","timestamp":1784354897338,"version":"3.55.0"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,6,10]],"date-time":"2005-06-10T00:00:00Z","timestamp":1118361600000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:p><jats:bold>Abstract\u2003<\/jats:bold><jats:bold> Aim:<\/jats:bold> To compare bacillus Calmette\u2010Guerin (BCG) with epirubicin in adjuvant therapy of superficial bladder transitional cell carcinoma, with respect to recurrence, progression and survival. Prognostic factors are also evaluated.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Between October 1991 and September 1999, all patients harboring superficial bladder cancers (Ta or T1) with any of the relevant criteria (stage\u2003&gt;\u2003a, grade\u2003&gt;\u20031, size\u2003&gt;\u20031\u2003cm, multiple or recurrent tumors), after complete transurethral resection were randomized to receive either 81\u2003mg Connaught strain BCG or 50\u2003mg epirubicin. Patients with recurrences were eligible to crossover, even repeatedly, until progression. Recurrence, progression and survival were analyzed in relation to initial treatment, patient characteristics and tumor characteristics.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> There were 209 patients included in the study, 149 men and 60 women. The mean age was 69.9\u2003years (range, 24\u201392). The BCG group consisted of 102 patients and the epirubicin group contained 107 patients. Final analysis was made at a median follow up of 23, 47 and 61\u2003months for recurrence, progression and survival, respectively. The 10\u2010year Kaplan\u2010Meier estimates for recurrence\u2010free, progression\u2010free and disease\u2010specific survival were 61%, 78% and 80%, respectively, for the BCG group. The corresponding figures were 32%, 74% and 92%, respectively, for the epirubicin group. Time to recurrence differed significantly between two treatment groups (<jats:italic>P<\/jats:italic>\u2003=\u20030.0004). Multiplicity increased the risk of recurrence, while grading influenced recurrence, progression and disease specific survival.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Bacillus Calmette\u2010Guerin prolonged time to recurrence when compared with epirubicin. Grading was shown to be a universal prognostic factor for recurrence, progression and disease specific survival.<\/jats:p>","DOI":"10.1111\/j.1442-2042.2005.01064.x","type":"journal-article","created":{"date-parts":[[2005,6,10]],"date-time":"2005-06-10T10:25:22Z","timestamp":1118399122000},"page":"449-455","source":"Crossref","is-referenced-by-count":23,"title":["Twelve\u2010year follow up of a randomized prospective trial comparing bacillus Calmette\u2010Guerin and epirubicin as adjuvant therapy in superficial bladder cancer"],"prefix":"10.1111","volume":"12","author":[{"given":"CHI WAI","family":"CHENG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SIU FOON PETER","family":"CHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LUNG WAI","family":"CHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHI KWOK","family":"CHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHI FAI","family":"NG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HO YUEN","family":"CHEUNG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHU YIN EDDIE","family":"CHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WAI SANG","family":"WONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FERNAND MAC\u2010MOUNE","family":"LAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KA FAI","family":"TO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MIU LING","family":"LI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,6,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67975-X"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)46972-2"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65396-5"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36198-0"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930901)72:5<1749::AID-CNCR2820720539>3.0.CO;2-8"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686918"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65966-6"},{"key":"e_1_2_7_9_2","first-page":"118","article-title":"First results of a phase III study comparing BCG and epirubicin in TIS of the bladder: an EORTC GU Group study","volume":"39","author":"De Reijke TM","year":"2001","journal-title":"Eur. Urol."},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200308000-00020"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37707-8"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1404"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64273-5"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199707000-00017"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66333-1"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.9.1450"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)40575-1"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240501323"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04360.x"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-2042.2005.01064.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-2042.2005.01064.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T07:46:17Z","timestamp":1697355977000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-2042.2005.01064.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1111\/j.1442-2042.2005.01064.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-2042.2005.01064.x","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}